Oncology News | pharmaphorum

News

NICE updates on controversial multiple myeloma decisions

NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether.

News

MSD adds bispecific cancer antibody via $1.3bn Curon deal

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies.

News

Second time lucky at FDA for Citius' lymphoma drug

At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago.

News

Person with their hand covering their face

More bad news for TIGIT as MSD stops another trial

Another TIGIT trial failure has been abandoned, casting a shadow once again over the target as a cancer immunotherapy strategy.

News

Servier bags FDA okay for glioma drug from $2bn Agios buy

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.

News

Mallinckrodt sells Therakos unit on at a discount

Ireland-headquartered pharma group Mallinckrodt has agreed to divest its subsidiary Therakos to private equity firm CVC Capital Partners for $925 million, well below the $1.33 billion it pa

NICE updates on controversial multiple myeloma decisions

MSD adds bispecific cancer antibody via $1.3bn Curon deal

Second time lucky at FDA for Citius' lymphoma drug

More bad news for TIGIT as MSD stops another trial

Servier bags FDA okay for glioma drug from $2bn Agios buy

Mallinckrodt sells Therakos unit on at a discount

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

News

Editor's Picks